Tirzepatide (Zepbound, 15 mg weekly), SURMOUNT-1, 72 weeks: mean weight loss approximately 22.5%
Clin Transl Allergy 1(1):3
In cell experiments, GLP-1 was found to have more mechanisms that may inhibit liver fat synthesis, such as FAM3A, NRF2, NaB, SHP1/AMPK, NLRP3, FGF21, IRS2, and other signaling pathways, which also provided direct evidence for the role of GLP-1R in the regulation of lipid metabolism in the liver
Silverman DH, Alavi A
Many pharmaceutical companies have decided that the benefits outweigh the risks
CHICAGO Bread and baked foods companies can meet the needs of GLP-1 weight-loss drug users through product innovation that adds nutrition, especially more fiber, said Colleen Zammer, vice president of varietal solutions growth and corporate innovation at Bay State Milling Co